Skip to main content

Advertisement

SpringerLink
Log in

Neurologic complications of chemotherapy for children with cancer

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Survival rates for children with cancer have increased dramatically over the past few decades. Development of new chemotherapeutic agents and the expanded use of older agents have had a major impact on this celebrated improvement. Chemotherapy can have, however, significant toxicity on the nervous system. The most common neurologic complications involve acute alterations in consciousness, leukoencephalopathy, seizures, cerebral infarctions, paralysis, neuropathy, and ototoxicity. Most of the information on toxicity comes from prospective reports and the adult patient population. Methotrexate, cyclosporin, and platinum compounds are the most frequently cited. No prospective studies have been done to evaluate chemotherapyinduced neurotoxicity in the pediatric population, and the exact incidence of such complications is unknown. Such investigation is greatly needed, as it may lead to a better understanding of how chemotherapy affects the nervous system and ultimately help develop more strategies to prevent drug-related neurotoxicity in pediatric cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. DiMario FJJr, Packer RJ: Acute mental status changes in children with systemic cancer. Pediatrics 1990, 85:353–360.

    PubMed  Google Scholar 

  2. Pratt CB, Green AA, Horowitz ME, et al.: Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986, 4:1253–1261.

    PubMed  CAS  Google Scholar 

  3. Pelgrims J, De VosF, Vanden BrandeJ, et al.: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000, 82:291–294. The study evaluated the neuroprotective effect of methylene blue in patients with ifosfamide-induced encephalopathy. The researchers conclude that methylene blue is an effective treatment for ifosfamideinduced encephalopathy and suggest that it may also be used as a prophylactic agent. Further studies with this agent are warranted.

    Article  PubMed  CAS  Google Scholar 

  4. Kupfer A, Aeschlimann C, Cerny T: Methylene blue and neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 1996, 50:249–252.

    Article  PubMed  CAS  Google Scholar 

  5. Ray M, Marwaha RK, Trehan A: Chemotherapy related fatal neurotoxicity during induction in acute lymphoblastic leukemia. Indian J Pediatr 2002, 69:185–187. This article reports fatal toxicity in two children during induction therapy for acute lymphoblastic leukemia that was attributable to treatment.

    PubMed  Google Scholar 

  6. Maytal J, Grossman R, Yusuf FH, et al.: Prognosis and treatment of seizures in children with acute lymphoblastic leukemia. Epilepsia 1995, 36:831–836.

    Article  PubMed  CAS  Google Scholar 

  7. Mahoney DHJr, Shuster JJ, Nitschke R, et al.: Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy—a Pediatric Oncology Group study. J Clin Oncol 1998, 16:1712–1722.

    PubMed  CAS  Google Scholar 

  8. DukesMN: Meyler’s Side Effects of Drugs. Amsterdam: Excerpta Medica Foundation; 2000.

    Google Scholar 

  9. Hurwitz RL, Mahoney DHJr, Armstrong DL, et al.: Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 1988, 16:216–219.

    Article  PubMed  CAS  Google Scholar 

  10. Moure JM, Whitecar JPJr, Bodey JP: Electroencephalogram changes secondary to asparaginase. Arch Neurol 1970, 23:365–368.

    PubMed  CAS  Google Scholar 

  11. Gleeson JG, dePlessis AJ, Barnes PD, Riviello J: Cyclosporin A acute encephalopathy and seizure syndrome in childhood: clinical features and risk of seizure recurrence. J Child Neurol 1998, 13:336–344.

    PubMed  CAS  Google Scholar 

  12. Gijtenbeck JM, van de Bent MJ, Vecht CJ: Cyclosporine neurotoxicity: a review. J Neurol 1999, 246:339–346.

    Article  Google Scholar 

  13. Aur RJ, Simone JF, Verzosa MS, et al.: Childhood acute lymphocytic leukemia study VIII. American Cancer Society 1978, 42:2123–2134.

    CAS  Google Scholar 

  14. Lovblad KO, Kelkar P, Ozdoba C, et al.: Pure methotrexate encephalapathy presenting with seizures: CT and MRI feature. Pediatr Radiol 1998, 28:86–91.

    Article  PubMed  CAS  Google Scholar 

  15. PochedlyC: Neurotoxicity due to CNS therapy for leukemia. Med Pediatr Oncol 1977, 3:101–105.

    Article  PubMed  CAS  Google Scholar 

  16. Kishi T, Tanaka Y, Ueda K: Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy. Cancer 2000, 89:925–931.

    Article  PubMed  CAS  Google Scholar 

  17. Kimmel DW, Wijdicks EF, Rodrigues M: Multifocal inflammatory leukoencephalopathy associated with levamisole therapy. Neurology 1995, 45:374–376.

    PubMed  CAS  Google Scholar 

  18. Matsumoto S, Nishizawa S, Murakami M, et al.: Carmocurinduced leukoencephalopathy: MRI. Neuroradiology 1995, 37:649–652.

    Article  PubMed  CAS  Google Scholar 

  19. Gonzalez H, Bolgert F, Camporo P, Lebland V: Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther 1999, 41:183–186.

    Article  PubMed  CAS  Google Scholar 

  20. Vidarsson B, Mosher DF, Salamat MS, et al.: Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol 2002, 70:51–54. The article describes the neurotoxic side effects of fludarabine and suggests its may increase the risk of progressive multifocal leukoencephalopathy in patients with lymphoproliferative diseases.

    Article  PubMed  Google Scholar 

  21. Packer RJ, Rorke LB, Lange BJ, et al.: Cerebrovascular accidents in children with cancer. Pediatrics 1985, 76:194–201.

    PubMed  CAS  Google Scholar 

  22. Antonini G, Ceschin V, Morino S, et al.: Early neurologic complications following allogeneic bone marrow transplant for leukemia: a prospective study. Neurology 1998, 50:1441–1445.

    PubMed  CAS  Google Scholar 

  23. Guerrero A, Perez-Simon JA, Gutierrez N, et al.: Neurological complications after autologous stem cell transplantation. Eur Neurol 1999, 41:48–50.

    Article  PubMed  CAS  Google Scholar 

  24. ReddinguisR: Dural sinus thrombosis in patients with cancer. Med Pediatr Oncol 1997, 29:296A.

    Article  Google Scholar 

  25. Fleischhack G, Solymosi L, Reiter A, et al.: Imaging methods in diagnosis of cerebrovascular complications with L-asparaginase therapy. Klin Padiatrie 1994, 20:334–341.

    Article  Google Scholar 

  26. Kardos M, Grexa E, Kajtar P: Neurologic complications during chemotherapy of children with acute lymphoid leukemia. Orvosi Hetilap 1992, 133:1111–1115.

    PubMed  CAS  Google Scholar 

  27. Kingma A, Tamminga RY, Kamps WA, et al.: Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia andother neuropsychological deficits. Pediatr Hematol Oncol 1993, 10:303–309.

    PubMed  CAS  Google Scholar 

  28. Ott N, Ramsay NK, Priest JR, et al.: Sequelae of thrombotic or hemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia. Am J Ped Hematol Oncol 1988, 10:191–195.

    Article  CAS  Google Scholar 

  29. Yim YS, Mahoney DHJr, Oshman DG: Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 1991, 67:2058–2061.

    Article  PubMed  CAS  Google Scholar 

  30. Gijtenbeck JM, vande BentMJ, Vecht CJ: Cyclosporine neurotoxicity: a review. J Neurol 1999, 246:339–346.

    Article  Google Scholar 

  31. Gagliano RG, Costanzi JJ: Paraplegia following intrathecal methotrexate: report of a case and review of the literature. Cancer 1976, 37:1663–1668.

    Article  PubMed  CAS  Google Scholar 

  32. Dunkelman H, Earl HM, Twelves C: Acute reversible neurological deficit following intrathecal themotherapy. Cancer Chemother Pharmacol 1991, 27:329–330.

    Article  PubMed  CAS  Google Scholar 

  33. Ozon A, Topaloglu H, Cila A, et al.: Acute ascending myelitis and Encephalopathy after intrathecal cytosine arabinoside and methotrexate in an adolescent boy with acute lymphocytic leukemia. Brain Dev 1994, 16:246–248.

    Article  PubMed  CAS  Google Scholar 

  34. Re D, Schwenk A, Hegener P, et al.: Guillain-Barre syndrome in a patient with non-Hodgkin’s lymphoma. Ann Oncol 2000, 11:217–220.

    Article  PubMed  CAS  Google Scholar 

  35. Adams C, August CS, Maguire H, et al.: Neuromuscular complications of bone marrow transplantation. Pediatr Neurol 1995, 43:1711–1714.

    Google Scholar 

  36. PosnerJB: Neurologic Complications of Cancer. Philadelphia: FA Davis; 1995.

    Google Scholar 

  37. AntunesN: Acute neurologic complications in children with systemic cancer. J Child Neurol 2000, 15:705–716. This comprehensive review goes over neurologic complications of systemic cancer and was based on the author’s experience as the consulting pediatric neurologist at a major cancer center.

    Article  PubMed  CAS  Google Scholar 

  38. Ding D, Wang J, Salvi RJ: Early damage in the chinchilla vestibular sensory epithelium from carboplatin. Audiology Neuro-Otology 1997, 2:155–267.

    Article  PubMed  CAS  Google Scholar 

  39. Screnci D, McKeage R: Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorganic Biochem 1999, 77:105–110.

    Article  CAS  Google Scholar 

  40. Neuwalt EA, Brummett RE, Remsen LG, et al.: In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res 1996, 56:706–709.

    Google Scholar 

  41. Wasserstein PH, Honig LS: Parkinsonism during cyclosporin treatment. Bone Marrow Transplant 1996, 18:649–650.

    PubMed  CAS  Google Scholar 

  42. Brashear A, Seimers E: Focal dystonia after chemotherapy: a case series. J Neurooncol 1997, 34:163–167.

    Article  PubMed  CAS  Google Scholar 

  43. Pranzatelli MR, Mott SH, Pavlakis SG, et al.: Clinical spectrum of secondary parkinsonism in childhood: a reversible disorder. Pediatr Neurol 1994, 10:131–140.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Children’s Hospital of Alabama, 1600 7th Avenue South, Suite 512 ACC, 35233, Birmingham, AL, USA

    Alyssa T. Reddy MD & Kerry Witek RPh

Authors
  1. Alyssa T. Reddy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kerry Witek RPh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reddy, A.T., Witek, K. Neurologic complications of chemotherapy for children with cancer. Curr Neurol Neurosci Rep 3, 137–142 (2003). https://doi.org/10.1007/s11910-003-0065-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-003-0065-2

Keywords

Search

Navigation